Anagenics (ASX:AN1) reported a revenue of AU$893,000 in the fiscal third quarter, falling from AU$1.3 million it reported in the fiscal second quarter, according to a Friday Australian bourse filing.

Its underlying net profit after tax came in at AU$138,000, down from AU$275,000 in the prior quarter.

It noted that its revenue and other income remained at 63% of the first fiscal quarter figures, following its recent restructuring. The decline in sales was attributed to the divestment of the Face MediGroup business. Sales during the quarter were also impacted by a one-off warehousing

transition from 3PL to an in-house service.

Following the restructuring, operating expenses have been recalibrated to 25% of fiscal Q1 levels.